Previous 10 | Next 10 |
Treating patients through stem cell research and regenerative medicines has emerged in popularity in the life sciences sector, although controversy has circulated this relatively new and upcoming therapeutic area for years. As described by the US National Institutes of Health , stem cells...
Alexion Pharmaceuticals (NASDAQ: ALXN ) initiated with Buy rating and $125 (15% upside) price target at SunTrust. More news on: Alexion Pharmaceuticals, Inc., Amgen Inc., Arcus Biosciences, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
NEW YORK and SHANGHAI , Nov. 11, 2019 /PRNewswire/ -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that ...
Cellular Biomedicine Group, Inc. (CBMG) Q3 2019 Earnings Conference Call November 6, 2019 04:30 pm ET Company Participants Derrick Li - Head of Strategy, Investor Relations Tony Liu - Chief Executive Officer and Chief Financial Officer Conference Call Participants Madhu Kumar...
Image source: The Motley Fool. Cellular Biomedicine Group Inc (NASDAQ: CBMG) Q3 2019 Earnings Call Nov 6, 2019 , 4:30 p.m. ET Operator Continue reading
Cellular Biomedicine (NASDAQ: CBMG ): Q3 GAAP EPS of -$0.82 misses by $0.15 . More news on: Cellular Biomedicine Group, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
NEW YORK and SHANGHAI , Nov. 6, 2019 /PRNewswire/ -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today repo...
NEW YORK and SHANGHAI , Oct. 30, 2019 /PRNewswire/ -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced ...
Deals and Financings Jiangsu Chia Tai Fenghai Pharma ((CTFH)) signed a $200-million agreement with Insilico Medicine, an AI drug discovery company headquartered in Hong Kong, to discover two triple-negative breast cancer candidates, aiming at previously undruggable targets. In September, I...
NEW YORK and SHANGHAI , Oct. 2, 2019 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today ann...
News, Short Squeeze, Breakout and More Instantly...
Cellular Biomedicine Group Inc. Company Name:
CBMG Stock Symbol:
NASDAQ Market:
Cellular Biomedicine Group Inc. Website:
Cellular Biomedicine Group, Inc. Announces Completion of Merger PR Newswire ROCKVILLE, Md. and SHANGHAI , Feb. 19, 2021 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG" or the "Company") today announced the completion of the merger (th...
Cellular Biomedicine Group, Inc. Stockholders Approve Merger PR Newswire ROCKVILLE, Md. and SHANGHAI , Feb. 8, 2021 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG" or the "Company") announced that, at the Company's special meeting...
Leading Proxy Advisory Firms Glass Lewis and ISS Recommend Cellular Biomedicine Group Stockholders Vote FOR Proposed Merger PR Newswire ROCKVILLE, Md. and SHANGHAI , Jan. 28, 2021 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) ("Company,...